A clinical trial with about 30,000 participants found that Sanofi's Fluzone High-Dose vaccine offered better protection against influenza than the standard dose in adults 65 and older. Sanofi plans to submit data to the FDA by early next year to support a change in the vaccine's label.

Full Story:

Related Summaries